Page last updated: 2024-11-08

piperitenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

piperitenone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID381152
CHEMBL ID54161
CHEBI ID17304
SCHEMBL ID220677
MeSH IDM0130989

Synonyms (39)

Synonym
CHEBI:17304 ,
NSC667470 ,
p-mentha-1,4(8)-dien-3-one
2-cyclohexen-1-one, 3-methyl-6-(1-methylethylidene)-
3-methyl-6-(1-methylethylidene)-2-cyclohexen-1-one
6-isopropylidene-3-methyl-cyclohex-2-en-1-one
NCI60_023460
nsc-667470
C01951
piperitenone
491-09-8
inchi=1/c10h14o/c1-7(2)9-5-4-8(3)6-10(9)11/h6h,4-5h2,1-3h3
hkzqjzifodolfr-uhfffaoysa-
pulespenone
3-methyl-6-propan-2-ylidenecyclohex-2-en-1-one
CHEMBL54161
3-terpinolenone
LMPR0102090056
ikr841w74d ,
p-menth-1,4(8)-dien-3-one
einecs 207-729-5
1-methyl-4-isopropylidene-1-cyclohexen-3-one
unii-ikr841w74d
fema no. 3560
3-methyl-6-(1-methylethylidene)cyclohex-2-en-1-one
SCHEMBL220677
3-methyl-6-(propan-2-ylidene)cyclohex-2-en-1-one
AKOS022504705
p-mentha-1,4(8)-dien-3-one [fhfi]
3-methyl-6-(1-methylethylidene)-2-cyclohexen-1-one #
6-isopropylidene-3-methyl-2-cyclohexenone
3-methyl-6-(1-methylethylidene)-2-cyclohexen-1-one, 9ci
fema 3560
Z1251353210
Q27102310
3-methyl-6-(propan-2-ylidene)cyclohex-2-enone
DTXSID10883402
CS-0086696
EN300-126320

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" longifolia plantlets and callus may be regarded as a potential source of a safe flavouring agent."( Mentha longifolia in vitro cultures as safe source of flavouring ingredients.
Bertoli, A; Krzyzanowska, J; Leonardi, M; Oleszek, W; Pistelli, L, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Further in vivo evaluations are strictly needed in order to evaluate the role of the bioavailability of the substance and the metabolic fate on its genotoxicity profile."( Genotoxicity assessment of piperitenone oxide: An in vitro and in silico evaluation.
Abete, L; Barile, F; Božović, M; Di Giacomo, S; Di Sotto, A; Izzo, AA; Mazzanti, G; Parisi, OA; Ragno, R; Vitalone, A, 2017
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
p-menthadien-3-one
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID174708Gastric cytoprotective activity in male wistar rat1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-cytoprotective activity relationship of simple molecules containing an alpha,beta-unsaturated carbonyl system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.82)18.7374
1990's3 (8.82)18.2507
2000's7 (20.59)29.6817
2010's18 (52.94)24.3611
2020's3 (8.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.92 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]